Targets › PLAU
6 programs from 6 companies in 6 trials: 2 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Infectious disease, Cardiovascular; next expected readout Mar 2027.
Serine protease that cleaves the inactive precursor plasminogen at a specific Arg-Val peptide bond, converting it into active plasmin. Secreted as an inactive zymogen, it is recruited and activated at the cell surface through interaction with the urokinase plasminogen activator receptor (uPAR). (UniProt, P00749)
Open in Phaseline: the race on PLAU, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Second Affiliated Hospital of Nanchang University | Urokinase Urokinase-type plasminogen activator exogenous protein | PLAU | Phase 4 | Aneurysmal Subarachnoid Hemorrhage | Jun 2027 |
| University of North Carolina, Chapel Hill | tissue plasminogen activator (tPA) Fibrinolytic enzyme; serine protease that converts plasminogen to plasmin | PLAU | Phase 4 | Pleural Infection Bacterial | Sep 2028 |
| First Affiliated Hospital Xi'an Jiaotong University | recombinant human prourokinase (rhPro-UK) serine protease that activates plasminogen to plasmin, promoting fibrinolysis | PLAU | Phase 3 | Acute Ischemic Stroke | Dec 2027 |
| The First Affiliated Hospital of Anhui Medical University | Recombinant Human Prourokinase for Injection (rhPro-UK) Serine protease that activates plasminogen to plasmin, promoting fibrin degradation and th | PLAU | Phase 3 | Acute Ischemic Stroke | Jun 2029 |
| Zhujiang Hospital | Nafamostat Mesilate Serine protease inhibitor; anticoagulant | F2, F2R, PLAU | Phase 2 | Continuous Renal Replacement Therapy (CRRT) | Mar 2027 |
| General Hospital of Shenyang Military Region | prourokinase Thrombolytic agent; plasminogen activator that converts plasminogen to plasmin | PLAU | Phase 2 | Acute Ischemic Stroke | Dec 2027 |
Acute Ischemic Stroke (3) Pleural Infection Bacterial (1) Aneurysmal Subarachnoid Hemorrhage (1) Continuous Renal Replacement Therapy (CRRT) (1)
protein or peptide (4), mixed (1), small molecule (1)
University of North Carolina, Chapel Hill (1) The First Affiliated Hospital of Anhui Medical University (1) General Hospital of Shenyang Military Region (1) First Affiliated Hospital Xi'an Jiaotong University (1) Second Affiliated Hospital of Nanchang University (1) Zhujiang Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.